UK biotech venture capital investment rebounded in Q1 2026, with total sector investment reaching £552 million (about $748 million), according to a report cited from the BioIndustry Association. Venture capital accounted for £516 million of that total, suggesting funding momentum carried into the new year after strength at the end of 2025. Analysts will watch whether this translates into more later-stage activity and IPO readiness over the rest of 2026.